Complicity theory: an explanation for the `coxib problem'?
Author:
- 1 June 2006
- journal article
- Published by SAGE Publications in Journal of the Royal Society of Medicine
- Vol. 99 (6) , 273-274
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Expression of Concern ReaffirmedNew England Journal of Medicine, 2006
- Risk of cardiovascular events and celecoxib: a systematic review and meta-analysisJournal of the Royal Society of Medicine, 2006
- Behavioural medicine: changing our behaviourBMJ, 2006
- Lessons from the withdrawal of rofecoxib: ***BMJ, 2004
- Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugsBMJ, 2004
- Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitorsGut, 2003
- Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?BMJ, 2002
- Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid ArthritisArchives of internal medicine (1960), 2002
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000